Get the Stockscreener App
3.87
2.03%
-0.08
After Hours:
3.70
-0.17
-4.39%
Q 32 Bio Inc stock is traded at $3.87, with a volume of 692.82K.
It is down -2.03% in the last 24 hours and up +100.52% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
See More
Previous Close:
$3.95
Open:
$3.99
24h Volume:
692.82K
Relative Volume:
1.87
Market Cap:
$47.20M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+53.57%
1M Performance:
+100.52%
6M Performance:
+101.56%
1Y Performance:
-91.64%
1-Day Range:
$3.45
$3.99
1-Week Range:
$2.70
$3.99
52-Week Range:
$1.345
$53.17
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
3.87 | 48.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Can Q32 Bio Inc. rally from current levelsQuarterly Trade Report & Precise Swing Trade Alerts - newser.com
Is Q32 Bio Inc. meeting your algorithmic filter criteriaJuly 2025 Pullbacks & Free Safe Capital Growth Stock Tips - newser.com
How institutional ownership impacts Q32 Bio Inc. stockWeekly Investment Summary & Stock Market Timing Techniques - newser.com
Applying sector rotation models to Q32 Bio Inc.July 2025 Summary & Verified Momentum Watchlists - newser.com
Detecting price anomalies in Q32 Bio Inc. with AI2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Published on: 2025-10-12 02:48:56 - newser.com
Will Q32 Bio Inc. stock split again soon2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Volatility clustering patterns for Q32 Bio Inc.Portfolio Return Report & AI Powered Trade Plan Recommendations - newser.com
Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffs - fiercebiotech.com
Published on: 2025-10-09 06:42:45 - newser.com
Is Q32 Bio Inc. stock poised for growthPortfolio Return Report & Low Drawdown Trading Strategies - newser.com
Key metrics from Q32 Bio Inc.’s quarterly dataLong Setup & Low Risk High Win Rate Picks - newser.com
Leading vs lagging indicators on Q32 Bio Inc. performanceAnalyst Downgrade & Entry and Exit Point Strategies - newser.com
Identifying reversal signals in Q32 Bio Inc.2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Morning Market Movers: XBIO, UPC, GLTO Spark Big Moves - RTTNews
Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation - Nasdaq
What analysts say about Q32 Bio Inc stockInsider Buying Signals & Outstanding Growth Strategies - earlytimes.in
Q32 Bio Trades At Lows While Betting On Immune Breakthroughs - Finimize
Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period (2025-2034) | DelveInsight - The AI Journal
Is now a turning point for Q32 Bio Inc.Quarterly Portfolio Summary & Community Consensus Trade Alerts - newser.com
Q32 Bio Inc. (NASDAQ:QTTB) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Will Q32 Bio Inc. stock recover after recent dropJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Applying Elliott Wave Theory to Q32 Bio Inc.Weekly Stock Report & Technical Confirmation Trade Alerts - newser.com
Why Q32 Bio Inc. is moving todayTrade Analysis Report & Expert Approved Momentum Ideas - newser.com
Q32 Bio Inc.’s Promising Alopecia Areata Treatment Trial Update - MSN
What to do if you’re stuck in Q32 Bio Inc.CPI Data & Safe Capital Growth Tips - newser.com
What MACD and RSI say about Q32 Bio Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
Layoff Tracker: CSL Vifor, Bolt Cut Staff - BioSpace
Relative strength of Q32 Bio Inc. in sector analysisEarnings Beat & High Conviction Buy Zone Picks - newser.com
How to forecast Q32 Bio Inc. trends using time seriesJuly 2025 Earnings & Reliable Momentum Entry Alerts - newser.com
Goldman Sachs Group Inc. Boosts Stake in Q32 Bio Inc. $QTTB - Defense World
A house dividing: Anaptysbio wants separate pipeline, royalty firms - BioWorld MedTech
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday - MSN
What drives Q32 Bio Inc stock priceCapital Gains Strategies & Low Entry Risk Stocks - earlytimes.in
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Q 32 Bio Inc Stock (QTTB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer |
Aug 26 '25 |
Sale |
1.80 |
2,990 |
5,385 |
58,384 |
| Kalowski Lee | CFO and President |
Aug 26 '25 |
Sale |
1.80 |
4,240 |
7,636 |
49,010 |
| Violette Shelia M. | Chief Scientific Officer |
Oct 15 '24 |
Option Exercise |
7.29 |
6,000 |
43,740 |
23,874 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):